Stellantis · client: Evera
With this agreement, Evera aims to rent 2,000 electric vehicles reconditioned by the Stellantis group by the end of 2027.
Company lists
Oncology, research tools, genomics, therapeutics, startups and more: the companies building life sciences in Massachusetts, with their founders, funding, team size and business models.
Funding, M&A, contract wins and launches involving 2,561 life sciences companies in Massachusetts, last 24 months: 246 M&A deals · 239 funding rounds · 79 Contracts · 7 launches. Newest first; companies and investors link to their Fliar profiles. Latest event in our news feed: Jun 2026.
With this agreement, Evera aims to rent 2,000 electric vehicles reconditioned by the Stellantis group by the end of 2027.
Apogee Therapeutics secured up to $1.3 billion in flexible, non-dilutive capital last month from Blackstone Life Sciences, including up to $800 million in synthetic royalty and access to…
In second place, gene editing company Editas Medicine announced a public offering of up to $319.4 million.
Under the terms of the agreement, Agios will obtain exclusive global rights to develop and commercialize cevidoplenib across all indications and will assume full responsibility for…
A Crowell & Moring team represented Kanders & Company in a complex carveout transaction in which Kanders acquired the biosecurity business of publicly traded Ginkgo Bioworks.
US cloud software systems provider for the life sciences industry Veeva Systems (NYSE: VEEV), which has a market cap of $26 billion, has acquired Israeli clinical trial and data…
On March 26, 2026, Pulmatrix entered into a definitive merger agreement with privately held Eos SENOLYTIX, a biotechnology company focused on gerotherapeutic peptides for aging-related…
And with the $595 million acquisition of Saga Diagnostics announced last month, Roche subsidiary Foundation Medicine will gain a new tool in the disease monitoring market with the firm's…
Eli Lilly and Company announced the acquisition of Kelonia Therapeutics, Inc., a biotechnology company focused on oncology drug development, for a consideration of up to $7 billion.
Trinity Capital Inc. (Nasdaq: TRIN) ... commitment of up to $35 million in equipment financing to Torus.
Eli Lilly and Company (NYSE: LLY) has agreed to acquire Ajax Therapeutics, Inc. in a cash deal worth up to $2.3 billion, including upfront and milestone-linked payments, to add a…
Tuesday, April 28, 2026 – Salesforce today announced that Moderna has selected Salesforce’s Agentforce Life Sciences for Customer Engagement to unify the biotechnology company’s global…
Salesforce today announced that Moderna has selected Salesforce’s Agentforce Life Sciences for Customer Engagement to unify the biotechnology company’s global commercial operations.
XRF Scientific (ASX: XRF) is acquiring Bruker AXS SE’s Combustion Gas Analysis (CGA) business for USD 4.0 million upfront, expanding its product portfolio and bringing manufacturing to…
The Solx-Caelux deal specifies 3 GW of hybrid modules over five years.
The announcement of the Kelonia-Therapeutics acquisition on Monday kicked off: up to 7 billion dollars in total, of which 3.25 billion dollars are due immediately.
Eli Lilly has entered a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion.
Collegium is acquiring AZSTARYS, related intellectual property, and global rights from Corium, a private company, for $650 million upfront.
RTW Biotech Opportunities Ltd, a London-listed investment company focused on the life sciences sector, said Tuesday that portfolio company Obsidian Therapeutics Inc. has agreed to merge…
Bellevue, Wash.-based Humanly, a startup that makes AI-powered interviewing tools for employers, announced it has acquired Anthill, a platform that uses AI to help companies connect with…
Algert Global LLC boosted its holdings in shares of Praxis Precision Medicines by 483.3% in the 3rd quarter.
Allspring Global Investments Holdings LLC bought a new stake in Praxis Precision Medicines, Inc. during the fourth quarter, according to the company in its most recent disclosure with…
Deerfield Management Company L.P. boosted its holdings in shares of Praxis Precision Medicines by 22.4% in the 3rd quarter.
Woodline Partners LP boosted its holdings in shares of Praxis Precision Medicines by 808.9% in the 3rd quarter.
Readystate Asset Management LP acquired a new stake in shares of Praxis Precision Medicines in the 3rd quarter valued at $5,786,000.
Adage Capital Partners GP L.L.C. boosted its holdings in shares of Praxis Precision Medicines by 13.3% in the 2nd quarter.
Korro Bio raised $85 million from a PIPE financing.
Solid Biosciences ... bringing in $240 million from a private placement.
Life Biosciences (Boston), a biotech focused on therapies to reverse cellular aging, announced an $80 million Series D round to fund a cellular rejuvenation platform.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has…
Few life sciences companies in Massachusetts publish revenue, so this list compares what is on record instead: recorded equity funding, team size, revenue model, age and stage. The 50 companies below lead on recorded funding and team size among 1,749 active companies.

Developer of mRNA-based therapeutics for a wide range of diseases
Gene therapyUS$2.78bn across 11 disclosed equity rounds
Darker bars = larger roundsFocus: mRNA therapeutics, nucleic acid modifications, and gene‑therapy vaccines for metabolic diseases
CPC A61K9/5123, A61K39/145, C12N15/67Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of osmotic pump for subcutaneous drug delivery
Drug deliveryUS$1.89bn across 19 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of transnational research for portfolio of cell and gene therapy
GenomicsUS$1.25bn across 4 disclosed equity rounds
Darker bars = larger roundsFocus: RNA delivery systems and circular RNA-based cellular reprogramming therapeutics
CPC C12N5/0696, A61K35/768, C07K14/7051Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapies for treating obesity and related conditions
ObesityUS$1.00bn across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Autonomous labs for biotechnology, empowering scientists to design the living world
GenomicsUS$795.75m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Engineering microbes for custom biosynthesis of drugs, flavors, proteins, and immune therapeutics
CPC C12N15/52, C12N15/815, C12P7/42Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

AI-based drug research and development company
Generative aiUS$783.50m across 5 disclosed equity rounds
Darker bars = larger roundsFocus: Immuno‑oncology therapeutics: STING pathway modulators and PI3Kβ inhibitor drug candidates
CPC A61P35/00, C07D498/04, C07D311/22Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of immunotherapeutics for immunological and cancer diseases
ImmunotherapyUS$717.24m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of a platform for generating novel protein-based therapeutic modalities
ImmunologyUS$693.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C07K16/104, G16B15/20, C07K16/244Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases
ImmunologyUS$637.00m across 9 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders
NeurologyUS$612.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of new genome engineering technology for treating multiple diseases
Life sciences platforms and toolsUS$610.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of AI-powered autonomous scientific research platforms
Life sciences techUS$550.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of cell-penetrating mini-proteins to target intracellular disease drivers
OncologyUS$530.90m across 7 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of drug discovery platform and study protein motion
Life sciences techUS$520.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Small-molecule FGFR and PI3Kα kinase inhibitors for oncology applications
CPC C07D487/04, C07D471/04, A61K31/519Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

AI-enabled bioinformatics platform for drug discovery and biomarker development
Life sciences techUS$509.76m across 8 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Proton therapy systems for oncology
OncologyUS$500.18m across 11 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Diabetes monitoring and management systems
DiabetesEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of a gene transplantation platform for humanizing pig cells
GenomicsUS$481.42m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Genetically engineered livestock for xenotransplant organ compatibility
CPC C12N5/0656, C12N15/8509, C12N5/0676Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Mobile health platform for doctors to manage clinical trials
Life sciences techUS$477.62m across 6 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of antibodies for the treatment of SARS-CoV-2
Infectious diseasesUS$466.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of miniaturized MRI platforms for clinical diagnostics
Infectious diseasesUS$454.30m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer
ImmunologyUS$451.77m across 5 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutic antibodies targeting KLRG1 for immune‑mediated diseases and leukemias
CPC C07K16/2851, C07K16/28Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of drugs for the treatment of cancer
OncologyUS$450.00m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of RNA therapeutics
Diversified pharmaceuticalsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of a medical device for the treatment of Alzheimer's disease
NeurologyUS$420.27m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics for allergic and inflammatory diseases
ImmunologyUS$400.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of small molecule and vaccine therapeutics for cancer and immunology disorders
ImmunotherapyUS$379.70m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Bispecific therapeutic proteins and heterobifunctional degraders for targeted cancer immunotherapy
CPC C07D413/14, A61P37/04, C07K16/468Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of next-generation switchable CAR T-cell immunotherapies
ImmunotherapyUS$362.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of fluorescence-guided imaging technologies to help surgeons detect residual cancer tissue during operations
OncologyUS$360.80m across 11 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of B cell therapies for multiple therapeutic areas
Cell therapyUS$356.00m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics to treat infectious diseases
Microbiome therapeuticsUS$350.49m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Live biotherapeutic products targeting gut microbiome dysbiosis and related diseases
CPC A61K35/74, C12N1/04, A61K35/742Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Innovating diabetes management with automated bionic pancreas technology
DiabetesUS$348.92m across 9 disclosed equity rounds
Darker bars = larger roundsFocus: Wearable bihormonal patch infusion pumps with smart dosing algorithms and flexible drive mechanisms
CPC A61M5/1723, G06F8/656, A61M5/1407Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of small molecule based therapeutics
Life sciences platforms and toolsUS$346.22m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of Endoscopic procedure for type - 2 diabetes
Metabolic diseasesUS$345.27m across 7 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of smart labs and lab spaces
Life sciences techUS$334.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: IoT-based communication and control systems for smart building automation and modular devices
CPC H04J13/00, H04B10/116, G07C9/00309Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of radiopharmaceuticals for solid tumor cancers
OncologyUS$331.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Targeted cancer therapeutics using engineered miniprotein ligands and conjugates
CPC A61K51/088, A61P35/00, C07K14/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Developer of engineered cell and gene therapies for multiple diseases
OncologyUS$325.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Engineered cytokine fusion proteins and regulated cell‑therapy platforms for cancer immunotherapy
CPC C12N9/003, C12N5/0636, C12N9/88Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics to treat neuropsychiatric disorders
NeurologyUS$325.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of genetic therapies for a wide range of diseases
GenomicsFocus: Lipid nanoparticle delivery systems for genome‑editing therapeutics targeting disease genes
CPC C12N15/11, A61K48/005, C12N15/1137Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapies for cancer treatment
OncologyUS$313.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of peptide therapeutics for the treatment of severe diseases
OncologyFocus: Design and synthesis of stapled peptide therapeutics for targeted drug delivery
CPC A61K9/0019, C07K7/56, A61K38/10Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of genomic technologies and drug discovery platform
GenomicsUS$304.10m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: CRISPR nucleases and reverse transcriptase enzymes for genome editing platforms
CPC C12N9/22, C12N15/113, C12N15/11Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of integrated solutions for next-generation antibody drug development
GenomicsUS$301.11m across 5 disclosed equity rounds
Darker bars = larger roundsFocus: Precise genome editing knock‑in technology for targeted DNA insertion
CPC A01K67/0275Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of novel drugs from fungi via genome mining and recombinant overexpression
Life sciences platforms and toolsUS$300.07m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of AI and real-world data solutions for life sciences
Data as a serviceUS$300.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in electrical & electronics
CPC H04N7/17318, G06Q30/02, G06F16/4387Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

AI-powered platform for drug discovery and development
Life sciences techUS$300.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Organ-on-chip 3D tissue platforms and ubiquitin‑targeted small‑molecule therapeutics
CPC C07D267/14, G01N33/4833, C07D401/12Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

AI-powered drug design and development platform
Life sciences techUS$294.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven drug discovery and cellular diagnostic platforms using heterocyclic modulators
CPC C07D471/04, G16B40/20, G16B25/10Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics for viral diseases
Infectious diseasesUS$293.43m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics to treat cystic fibrosis
ImmunologyUS$293.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of a prosthetic hand and EEG headband for brain signal
NeurologyUS$291.80m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Neurofeedback brain‑computer interfaces for personalized learning, attention monitoring, and robot control
CPC G06F3/015, A61B5/168, G06F3/014Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
No matching company in this list.
This page shows the top 50. Radar has the complete, filterable list with contacts and live company signals.
Open life sciences in Massachusetts on RadarDiscover top life sciences companies in Massachusetts across oncology, genomics, research tools, and therapeutics. Compare life sciences startups in Massachusetts by their scientific focus.
Life sciences companies developing cancer drugs, diagnostics, and immunotherapies.

Developer of mRNA-based therapeutics for a wide range of diseases
Gene therapy
Developer of immunotherapeutics for immunological and cancer diseases
Immunotherapy
Developer of a platform for generating novel protein-based therapeutic modalities
Immunology
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases
Immunology
Developer of cell-penetrating mini-proteins to target intracellular disease drivers
OncologyProviders of instruments, platforms, assays, and research technology.

AI-based drug research and development company
Generative ai
Provider of new genome engineering technology for treating multiple diseases
Life sciences platforms and tools
Developer of AI-powered autonomous scientific research platforms
Life sciences tech
Developer of drug discovery platform and study protein motion
Life sciences tech
AI-enabled bioinformatics platform for drug discovery and biomarker development
Life sciences techCompanies applying genomics, clinical sequencing, and gene therapy.

Provider of transnational research for portfolio of cell and gene therapy
Genomics
Autonomous labs for biotechnology, empowering scientists to design the living world
Genomics
Provider of new genome engineering technology for treating multiple diseases
Life sciences platforms and tools
Developer of a gene transplantation platform for humanizing pig cells
Genomics
Developer of genetic therapies for a wide range of diseases
GenomicsDrug developers focused on neurological, rare, and infectious diseases.

Developer of a platform for generating novel protein-based therapeutic modalities
Immunology
Developer of antibodies for the treatment of SARS-CoV-2
Infectious diseases
Developer of a medical device for the treatment of Alzheimer's disease
Neurology
Developer of therapeutics for viral diseases
Infectious diseases
Developer of a diagnostic platform for sexually transmitted infections
Infectious diseasesRecently founded life sciences companies in Massachusetts.

Developer of therapies for treating obesity and related conditions
Obesity
Developer of AI-powered autonomous scientific research platforms
Life sciences tech
Developer of therapeutics for allergic and inflammatory diseases
Immunology
Developer of next-generation switchable CAR T-cell immunotherapies
Immunotherapy
Developer of radiopharmaceuticals for solid tumor cancers
OncologyLife sciences companies in Massachusetts with hiring activity.

Developer of mRNA-based therapeutics for a wide range of diseases
Gene therapy
Provider of transnational research for portfolio of cell and gene therapy
Genomics
Developer of therapies for treating obesity and related conditions
Obesity
Autonomous labs for biotechnology, empowering scientists to design the living world
Genomics
AI-based drug research and development company
Generative aiPublicly listed life sciences companies in Massachusetts.

Developer of mRNA-based therapeutics for a wide range of diseases
Gene therapy
Developer of therapies for treating obesity and related conditions
Obesity
Autonomous labs for biotechnology, empowering scientists to design the living world
Genomics
AI-based drug research and development company
Generative ai
Developer of immunotherapeutics for immunological and cancer diseases
ImmunotherapyThe most-installed Android apps published by life sciences companies headquartered in Massachusetts — 381K installs between them. 20 companies on this page publish at least one app; each company (legal entity) appears once, with its most-installed app.
The figures on this page come from Fliar’s company, funding, hiring and news data. Use it through the Investor Intelligence API and company data exports, or explore every company, founder and investor in Radar.
22,455 recorded equity rounds have gone to 27,407 life sciences companies in the United States — how much, at which stage, into which sub-sectors, from whom, and how Massachusetts compares. Debt, IPO and grant rounds are excluded.
US$13.54bn
US$37.38bn
5,603 rounds in the United States
last 24 months
Bars show US$ raised; the number under each year is equity rounds. 2026 is year to date. The peak year was 2021, with US$45.29bn across 1383 rounds.
Equity rounds over the last five years, 2,561 life sciences companies in Massachusetts among 27,407 in the United States.
Each deal appears in the events strip at the top of the page.
Go deeper in the life sciences landscape reports:
Life Sciences Industry Landscape of the United StatesThe financials above are one chapter. The full life sciences landscape of Massachusetts maps the whole industry — every segment, the capital behind it, the talent market and where the next opportunities are.
749 life sciences companies in Massachusetts have recorded equity funding, US$68.67bn in total. Totals and round dates describe the historical record; they are not current valuations.
Largest recorded equity totals, with the latest recorded round.
Gene therapyDeveloper of mRNA-based therapeutics for a wide range of diseases
Drug deliveryProvider of osmotic pump for subcutaneous drug delivery
GenomicsProvider of transnational research for portfolio of cell and gene therapy
ObesityDeveloper of therapies for treating obesity and related conditions
GenomicsAutonomous labs for biotechnology, empowering scientists to design the living world
Generative aiAI-based drug research and development company
ImmunotherapyDeveloper of immunotherapeutics for immunological and cancer diseases
ImmunologyDeveloper of a platform for generating novel protein-based therapeutic modalities
ImmunologyDeveloper of targeted therapeutics for cancer, metabolic and inflammatory diseases
NeurologyDeveloper of precision medicines for neuropsychiatric disorders and neurodegenerative disorders
Life sciences platforms and toolsProvider of new genome engineering technology for treating multiple diseases
Life sciences techDeveloper of AI-powered autonomous scientific research platforms
Founders
Details not available
OncologyDeveloper of cell-penetrating mini-proteins to target intracellular disease drivers
Life sciences techDeveloper of drug discovery platform and study protein motion
Life sciences techAI-enabled bioinformatics platform for drug discovery and biomarker development
OncologyProton therapy systems for oncology
Founders
Details not available
US$2.78bn across 11 disclosed equity rounds
Darker bars = larger roundsFocus: mRNA therapeutics, nucleic acid modifications, and gene‑therapy vaccines for metabolic diseases
CPC A61K9/5123, A61K39/145, C12N15/67Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$1.89bn across 19 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$1.25bn across 4 disclosed equity rounds
Darker bars = larger roundsFocus: RNA delivery systems and circular RNA-based cellular reprogramming therapeutics
CPC C12N5/0696, A61K35/768, C07K14/7051Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$1.00bn across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$795.75m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Engineering microbes for custom biosynthesis of drugs, flavors, proteins, and immune therapeutics
CPC C12N15/52, C12N15/815, C12P7/42Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$783.50m across 5 disclosed equity rounds
Darker bars = larger roundsFocus: Immuno‑oncology therapeutics: STING pathway modulators and PI3Kβ inhibitor drug candidates
CPC A61P35/00, C07D498/04, C07D311/22Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$717.24m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$693.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C07K16/104, G16B15/20, C07K16/244Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$637.00m across 9 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$612.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$610.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$550.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$530.90m across 7 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$520.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Small-molecule FGFR and PI3Kα kinase inhibitors for oncology applications
CPC C07D487/04, C07D471/04, A61K31/519Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$509.76m across 8 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$500.18m across 11 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Meet the people behind life sciences companies in Massachusetts. 1,256 of 1,749 companies list founders or leaders; where a public LinkedIn profile matches exactly, the expanded profile shows the photo, headline, location and education.
Companies whose recorded headcount rose the most between the two most recent team-size snapshots. A larger team is a signal of momentum, not of profitability.
Life sciences techHealthcare solutions leveraging data, technology, and AI to improve patient outcomes
NeurologyDeveloping therapeutics for treatment of pain and inflammation
Founders
Details not available
Life sciences platforms and toolsHepatoPac® and HepatoMune™ liver models (in vitro tools) for assessing drug metabolism & potential hepatotoxicity
Life sciences platforms and toolsManufacturer of diversified instrument systems for research purposes
NeurologyProvider of neuro medicines development and communication services
GenomicsDeveloper of automated instrumentation for pathogen detection
Women healthDeveloping live bio therapeutics to treat vaginal diseases
Drug deliveryProvider of drug delivery system for cancer treatment
Life sciences techRayyan is an AI assisted collaboration tool to conduct systematic literature reviews in far less time.
Founders
Details not available
Life sciences techProvider of supply chain management solutions for biotech, finance, and other industries
Founders
Details not available
NeurologyDeveloper of therapeutics for neuromuscular disorders
Life sciences platforms and toolsInnovative solutions for contamination-free liquid handling in life science assays
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$70.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Pharmaceutical formulations for ocular, immunoinflammatory and antiviral (filovirus) therapies
CPC A61K45/06, A61K38/13, A61K31/565Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$250.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Automated nucleic‑acid extraction and low‑volume sample‑prep cartridges for molecular diagnostics
CPC G01N21/6456, B01L3/502753, B01L3/0293Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Patents concentrated in chemistry & materials
CPC C09K8/582, C12N1/20, C12P3/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$15.35m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$56.22m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Life sciences companies in Massachusetts with at least one woman on the founding team. Expand a profile to meet the founders; teams can include both women and men.
Life sciences techDigital marketplace for life science products

GenomicsAutonomous labs for biotechnology, empowering scientists to design the living world
OncologyDeveloper of small molecule drugs for the treatment of cancer and inflammatory disease
GenomicsDeveloper of a platform for RNA-based products for life science industry
Life sciences techDeveloper of drug discovery platform and study protein motion
ImmunotherapyDeveloper of T cell therapies to harness the immune system against cancer
NeurologyDeveloper of precision medicines for neuropsychiatric disorders and neurodegenerative disorders
Life sciences techDeveloper of bioactive peptides derived from silk protein for skincare
GenomicsDeveloper of a gene transplantation platform for humanizing pig cells
DiabetesInnovating diabetes management with automated bionic pancreas technology
ImmunologyDeveloper of RNA-modifying drug candidates for the treatment of multiple disorders
Life sciences platforms and toolsDeveloper of novel drugs from fungi via genome mining and recombinant overexpression
US$55.75m across 5 disclosed equity rounds
Darker bars = larger rounds
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$795.75m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Engineering microbes for custom biosynthesis of drugs, flavors, proteins, and immune therapeutics
CPC C12N15/52, C12N15/815, C12P7/42Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$98.40m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$225.05m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: RNA‑based biopesticides and plant protection formulations targeting pathogens and insects
CPC C12P19/02, C12P19/34, A01N63/60Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$520.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Small-molecule FGFR and PI3Kα kinase inhibitors for oncology applications
CPC C07D487/04, C07D471/04, A61K31/519Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$158.30m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: TCR-mimic binding proteins for targeted cancer immunotherapy against tumor antigens
CPC C07K14/4748, C07K14/7051, A61K39/215Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$612.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$190.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Silk-based biopolymers for performance textiles, cosmetics, and hyaluronic‑acid medical fillers
CPC A61K8/64, D06M15/15, C09D189/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$481.42m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Genetically engineered livestock for xenotransplant organ compatibility
CPC C12N5/0656, C12N15/8509, C12N5/0676Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$348.92m across 9 disclosed equity rounds
Darker bars = larger roundsFocus: Wearable bihormonal patch infusion pumps with smart dosing algorithms and flexible drive mechanisms
CPC A61M5/1723, G06F8/656, A61M5/1407Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$181.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: RNA splicing modulators for treating neurodegenerative diseases
CPC C07D487/04, C07D401/14, C07D451/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$300.07m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Life sciences companies in Massachusetts founded in the last four years, newest first.
Life sciences techProvider of AI and data solutions for the life sciences industry

OrthopedicsDeveloper of targeted small-molecule therapies for musculoskeletal health and bone regeneration
Life sciences platforms and toolsDeveloper of artificial intelligence to analyze microbial ecosystems for medicine
Developer of precision medicines targeting cancer and other serious diseases
Founders
Details not available
Developer of novel mechanisms for the treatment of pulmonary arterial hypertension
Founders
Details not available
Provider of bioinformatics solutions and custom pipelines for genomic data analysis
Founders
Details not available
Developer of therapeutics for multiple diseases
Founders
Details not available
NeurologyDeveloper of therapies modulating neural pathways for addiction and neurological disorders
Founders
Details not available
Life sciences platforms and toolsDeveloper of AI-powered cell imaging platform for drug discovery
Founders
Details not available
Developer of an AI-powered platform for pharmaceutical research and development
Founders
Details not available
Manufacturer of endoluminal surgical robotic solutions for improved patient care
Founders
Details not available
ObesityDeveloper of therapies for treating obesity and related conditions

Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$1.00bn across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Companies with the most distinct news events in the last 24 months across the business press Fliar tracks.
Gene therapyDeveloper of mRNA-based therapeutics for a wide range of diseases
GenomicsDeveloper of RNA-targeted therapeutics for the treatment of rare and infectious diseases
Gene therapyDeveloper of RNA interference-based therapeutics for multiple disorders
Drug deliveryManufacturer of wearable, tubeless insulin delivery systems for diabetes management
Life sciences techPlatform that provides cloud and AI based solutions to track and trace pharmaceutical supply chains
Life sciences platforms and toolsManufacturer of diversified instrument systems for research purposes
Life sciences platforms and toolsProvider of services for manufacturing biological drugs
HematologyProvider of hematology products and solutions for the medical industry
Life sciences techAI-assisted platform for drug discovery and development
OncologyDeveloper of small molecule drugs for the treatment of cancer and inflammatory disease
Life sciences techProvider of sample storage and management solutions
ImmunotherapyDeveloper of targeted therapies for the treatment of cancer
US$2.78bn across 11 disclosed equity rounds
Darker bars = larger roundsFocus: mRNA therapeutics, nucleic acid modifications, and gene‑therapy vaccines for metabolic diseases
CPC A61K9/5123, A61K39/145, C12N15/67Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$120.40m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Wearable automated insulin pump systems for continuous glucose‑controlled drug delivery.
CPC A61M5/1723, A61M5/14248, G16H20/17Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$230.00m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Bioprocess analytics and purification: spectroscopic monitoring, chromatography media, affinity ligands.
CPC C07K14/31, B01D63/02, B01D15/22Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$247.28m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Wearable assistive exosuits for posture correction and biomechanical feedback
CPC B25J9/0006, A61F2/68, G05B13/026Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$98.40m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Large-scale cryogenic biobanking: storage, handling, and tracking of biological samples
CPC F17C3/085, B67B7/182, A01N1/14Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$198.29m across 10 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
The most common specialisations among life sciences companies in Massachusetts. Open a company to see what it sells, who runs it and how far it has come.
325 life sciences companies in Massachusetts work in oncology. Shown: the best-documented.
Gene therapyDeveloper of mRNA-based therapeutics for a wide range of diseases
Developer of mRNA-based oncology treatments
ImmunotherapyDeveloper of targeted and immune-oncology drugs against cancer
OncologyDeveloper of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism
OncologyDeveloper of small molecule drugs for the treatment of cancer and inflammatory disease
Life sciences techDeveloper of drug discovery platform and study protein motion
OncologyDeveloper of therapeutics for the treatment of cancer
Rare diseasesDeveloper of precision therapy for genetically defined diseases
ImmunotherapyDeveloper of T cell therapies to harness the immune system against cancer
NeurologyDeveloper of Antibody-based drugs for the treatment of primary myopathies
ImmunologyDeveloper of small molecule protein degraders for multiple disorders
GenomicsDeveloper of drugs for the treatment of cancer
US$2.78bn across 11 disclosed equity rounds
Darker bars = larger roundsFocus: mRNA therapeutics, nucleic acid modifications, and gene‑therapy vaccines for metabolic diseases
CPC A61K9/5123, A61K39/145, C12N15/67Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$172.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Combination therapies targeting MAPK pathway and immune checkpoints for cancer treatment
CPC A61P35/00, A61K31/4375, C07D471/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$119.82m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Metabolic enzyme modulators for hematologic and metabolic disease therapy
CPC A61K31/53, C07D401/14, A61K31/496Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$98.40m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$520.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Small-molecule FGFR and PI3Kα kinase inhibitors for oncology applications
CPC C07D487/04, C07D471/04, A61K31/519Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$77.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Small-molecule kinase inhibitors targeting PI3K, ERBB2, and JAK2 for cancer therapy
CPC C07D471/04, A61K31/404, C07D487/08Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$158.30m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: TCR-mimic binding proteins for targeted cancer immunotherapy against tumor antigens
CPC C07K14/4748, C07K14/7051, A61K39/215Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$103.30m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutic myostatin and GLP‑1 pathway modulation for metabolic and muscle disorders
CPC C07K16/22, A61K39/3955, A61K39/395Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$197.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$165.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
278 life sciences companies in Massachusetts work in life sciences tech. Shown: the best-documented.
Life sciences techDigital marketplace for life science products

Life sciences techCloud-based platform for clinical research data analytics
Life sciences techProvider of AI and data solutions for the life sciences industry

Data as a serviceProvider of AI and real-world data solutions for life sciences
Life sciences techProvider of digital pathology image management system for clinical labs
Life sciences techPlatform that provides cloud and AI based solutions to track and trace pharmaceutical supply chains
Life sciences techAI-enabled bioinformatics platform for drug discovery and biomarker development
Life sciences techDeveloper of drug discovery platform and study protein motion
Life sciences techDeveloper of smart labs and lab spaces
Healthcare itProvider of an AI platform for clinical data analysis and insights
Life sciences techAI-based manufacturing processing and management tool for pharmaceutical industry
Life sciences techAI-powered platform for drug discovery and development
Founders
Details not available
US$55.75m across 5 disclosed equity rounds
Darker bars = larger rounds
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$300.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in electrical & electronics
CPC H04N7/17318, G06Q30/02, G06F16/4387Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$254.94m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven digital pathology analysis and tissue characterization using advanced machine learning models
CPC G06T7/0012, G16H50/30, G06F18/23Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$230.00m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$509.76m across 8 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$520.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Small-molecule FGFR and PI3Kα kinase inhibitors for oncology applications
CPC C07D487/04, C07D471/04, A61K31/519Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$334.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: IoT-based communication and control systems for smart building automation and modular devices
CPC H04J13/00, H04B10/116, G07C9/00309Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$133.74m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in computing, sensing & instrumentation
CPC G16H10/60, G06F21/6254, G06N5/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$246.96m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Remote digital workflow automation and video guidance for legacy manufacturing equipment
CPC G06Q10/10, H04N21/4542, H04W4/029Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$300.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Organ-on-chip 3D tissue platforms and ubiquitin‑targeted small‑molecule therapeutics
CPC C07D267/14, G01N33/4833, C07D401/12Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
255 life sciences companies in Massachusetts work in life sciences platforms and tools. Shown: the best-documented.
Life sciences platforms and toolsBioinspired medical solutions company developing advanced biomaterials for unmet clinical needs

Life sciences platforms and toolsHepatoPac® and HepatoMune™ liver models (in vitro tools) for assessing drug metabolism & potential hepatotoxicity
Life sciences platforms and toolsProvider of new genome engineering technology for treating multiple diseases
Life sciences platforms and toolsDeveloper of small molecule based therapeutics
Life sciences platforms and toolsDeveloper of assay kits for ultra-sensitive biomarker detection
Life sciences platforms and toolsDeveloper of in vitro models for drug development
Life sciences platforms and toolsDrug discovery company employing functional genomics technology
Life sciences platforms and toolsManufacturer of detection device for chemical analysis using mass spectrometry
Life sciences platforms and toolsDeveloper of novel drugs from fungi via genome mining and recombinant overexpression
GenomicsProvider of integrated solutions for next-generation antibody drug development
Life sciences platforms and toolsProvider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases
Life sciences platforms and toolsProvider of a biorepository of human clinical specimens

Focus: Peptide-based self‑assembling hydrogels for regenerative medicine and targeted drug/cell delivery
CPC C07K14/001, A61K38/02, A61K38/16Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$610.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$346.22m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$99.50m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Ultra-sensitive digital immunoassays for protein biomarkers in clinical diagnostics
CPC G01N33/6896, G01N33/54393, G01N33/54306Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$204.49m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C12M23/16, B01L3/502723, C12N5/0679Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$156.60m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$68.22m across 5 disclosed equity rounds
Darker bars = larger roundsFocus: Microfluidic sample preparation and compact mass spectrometry for rapid bio‑analysis
CPC H01J49/0095, H01J49/049, G01N27/44791Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$300.07m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$301.11m across 5 disclosed equity rounds
Darker bars = larger roundsFocus: Precise genome editing knock‑in technology for targeted DNA insertion
CPC A01K67/0275Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$11.86m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
248 life sciences companies in Massachusetts work in genomics. Shown: the best-documented.
Gene therapyDeveloper of RNA interference-based therapeutics for multiple disorders
GenomicsAutonomous labs for biotechnology, empowering scientists to design the living world
Developer of mRNA-based oncology treatments
Gene therapyDeveloper of therapeutics based on CRISPR/Cas9 technology for multiple diseases
GenomicsProvider of transnational research for portfolio of cell and gene therapy
GenomicsDeveloper of gene therapy using CRISPR base editing to treat diseases
Microbiome therapeuticsDeveloper of microbiome therapeutics to treat a wide range of diseases
GenomicsDeveloper of a platform for RNA-based products for life science industry
Rare diseasesDeveloper of therapeutics for rare genetic diseases
Cell therapyGenetically modifying hematopoietic stem cells to create RBC therapeutics in metabolic deficiencies, autoimmune disorders, and cancer
Founders
Details not available
Rare diseasesRNA medicines to transform human health, treating rare and common disorders
Life sciences platforms and toolsProvider of new genome engineering technology for treating multiple diseases
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$795.75m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Engineering microbes for custom biosynthesis of drugs, flavors, proteins, and immune therapeutics
CPC C12N15/52, C12N15/815, C12P7/42Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$85.02m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: CRISPR genome editing therapeutics for genetic diseases and protein replacement
CPC C12N15/113, C12N15/90, C12N15/88Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$1.25bn across 4 disclosed equity rounds
Darker bars = larger roundsFocus: RNA delivery systems and circular RNA-based cellular reprogramming therapeutics
CPC C12N5/0696, A61K35/768, C07K14/7051Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$222.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Base editing gene therapies and lipid nanoparticle delivery for genetic disease treatment
CPC C12N9/78, C12N9/22, C12N15/113Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$134.13m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Live bacterial therapeutics for gut microbiome modulation and infection/cancer treatment
CPC A61K35/742, A61K35/741, A61K35/74Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$225.05m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: RNA‑based biopesticides and plant protection formulations targeting pathogens and insects
CPC C12P19/02, C12P19/34, A01N63/60Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$210.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: CRISPR-based gene editing therapies for blood disorders and immune cell modulation
CPC C12N15/113, C12N9/22, C12N15/907Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$245.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C12N5/0641, A61K35/18, A61K35/12Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$84.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutic oligonucleotides for RNA interference, exon skipping, and gene modulation.
CPC C12N15/113, C12N15/111, C07H21/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$610.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
254 more company lists you can search, plus the Radar directory pages for each place.
No list matches. Try a shorter word.
We will reply with coverage, fields and pricing for your use case.
Filed revenue, profit and growth for every company on this page are available with a Radar account. Log in and you will come straight back here with all figures open.